Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19242261 | 1.00 | USP2 (0.36) | USP2ALDH1A1LMNACYP1A2TSHR | |
| SCHEMBL19069681 | 1.00 | USP2 (0.36) | USP2ALDH1A1LMNACYP1A2TSHR | |
| SCHEMBL92576 | 1.00 | — | — | |
| SCHEMBL12361078 | 1.00 | USP2 (0.36) | USP2ALDH1A1LMNACYP1A2TSHR | |
| SCHEMBL18610573 | 1.00 | USP2 (0.36) | USP2ALDH1A1LMNACYP1A2TSHR | |
| SCHEMBL13849408 | 1.00 | USP2 (0.36) | USP2ALDH1A1LMNACYP1A2TSHR | |
| SCHEMBL12361074 | 1.00 | USP2 (0.36) | USP2ALDH1A1LMNACYP1A2TSHR | |
| SCHEMBL18879736 | 1.00 | USP2 (0.36) | USP2ALDH1A1LMNACYP1A2TSHR | |
| Hydrochloric Acid SCHEMBL25345453 | 0.97 | USP2 (0.34) | USP2ALDH1A1LMNACYP1A2TSHR | |
| SCHEMBL3249011 | 0.97 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080146612-A1 | Novel Biaromatic Compounds, Inhibitors of the P2X7-Receptor | ASTRAZENECA AB (SE) | 2008-06-19 | — | — | US | disclosed |
| CN-101151239-A | Novel biaromatic compounds, inhibitors of the P2X7-receptor | ASTRAZENECA AB (SE) | 2008-03-26 | — | — | CN | disclosed |
| EP-1844003-A1 | NOVEL BIAROMATIC COMPOUNDS, INHIBITORS OF THE P2X7-RECEPTOR | AstraZeneca AB (SE) | 2007-10-17 | — | — | EP | disclosed |
| WO-2006080884-A1 | NOVEL BIAROMATIC COMPOUNDS, INHIBITORS OF THE P2X7-RECEPTOR | ASTRAZENECA AB (SE) | 2006-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146612-A1 | Novel Biaromatic Compounds, Inhibitors of the P2X7-Receptor | P2RX2, P2RX1, ADORA1 | USP2 4230/4885ALDH1A1 719/4885LMNA 3293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.